Los Angeles, California 90028

  • HIV

Purpose:

Participants receive culturally relevant and specifically tailored text messages based on the behavioral change theoretical constructs of Social Support Theory, Health Belief Model, and Social Cognitive Theory. Participants are randomized into one of three conditions for an 8-week intervention period: Group 1: culturally relevant theory-based text messages interactively transmitted by peer health educators (TXT-PHE); or, Group 2: the same culturally relevant theory-based text messages transmitted by automation (TXT-Auto); or, Group 3: assessment-only (AO) control with no theoretically based text messages. Participants in all three conditions receive brief weekly text-message assessments on their methamphetamine use and HIV sexual behaviors in the previous seven days. Data related to intervention costs as well as relative exposure to each theoretical construct will be examined to determine cost- and mechanism-effectiveness, respectively. The randomized three-group design uses repeated assessments at baseline, at the end of the 8-week intervention period, and at 3-, 6-, and 9-month post randomization follow-up. This study will determine the differential immediate and sustained effects of transmitting theory-based text messages by PHE (TXT-PHE) versus by automation (TXT-Auto), compared to an assessment-only (AO) control condition among out-of-treatment, methamphetamine-using MSM for reductions of methamphetamine use and HIV sexual risk behaviors. It is hypothesized that there will be significantly greater reductions in methamphetamine use and HIV sexual risk behaviors from text messages transmitted by PHE than by text messages transmitted by automation, which in turn will produce significantly greater reductions than the AO condition (PHE > TXT > AO). In addition, this study will determine the cost-effectiveness of TXT-PHE vs. TXT-Auto compared to AO for reducing methamphetamine use and HIV sexual risk behaviors. The investigators hypothesize that the TXT-PHE intervention will prove more cost-effective than TXT-Auto in reducing methamphetamine use and HIV sexual risk behaviors, while the TXT-Auto condition will prove more cost effective than the AO condition in reducing these same outcomes (PHE > TXT > AO).


Criteria:

Inclusion Criteria: - Self-identified MSM - Between the ages of 18 and 65 years - Methamphetamine use within the previous 3 months - Unprotected anal intercourse (insertive or receptive) with a non-primary male partner in the previous 6 months - Not currently in treatment or seeking methamphetamine abuse treatment - Able and willing to fully charge a cellular phone daily - Able and willing to provide informed consent - Able and willing to comply with study requirements Exclusion Criteria: - Does not identify as a MSM - Not between the ages of 18 and 65 years - Has not used methamphetamine in the previous 3 months - Has not had unprotected anal intercourse (insertive or receptive) with a non-primary male partner in the previous 6 months - Currently in treatment or seeking methamphetamine abuse treatment - Unable or unwilling to fully charge a cellular phone daily - Unable or unwilling to provide informed consent - Unable or unwilling to comply with study requirements - Unable to understand the Informed Consent Form - Determined to have a more serious psychiatric condition (SCID verified) that is beyond the safe enrollment of study procedures


NCT ID:

NCT02008526


Primary Contact:

Principal Investigator
Cathy J Reback, Ph.D.
Friends Research Institute, Inc.

Mitch Metzner, Ph.D.
Phone: (323) 463-1601
Email: mmetzner@friendsresearch.org


Backup Contact:

Email: jfletcher@friendsresearch.org
Jesse B Fletcher, Ph.D.
Phone: (323) 463-1601


Location Contact:

Los Angeles, California 90028
United States

Mitch Metzner, Ph.D.
Phone: 323-463-1601
Email: mmetzner@friendsresearch.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.